

彩云木叶化学成分及其抗炎活性研究

阳 航¹, 邹情雅², 陈 宇¹, 路艳霞¹, 刘梦元¹, 李路军^{1,3,4*}, Paul W. Paré^{2*}¹药物高通量筛选国家与地方联合工程研究中心, 生物催化与酶工程国家重点实验室, 中药生物技术湖北省重点实验室, 湖北大学, 武汉 430062;²美国德州理工大学 化学与生物化学系, 拉伯克 79409; ³甘肃百草中药材种植有限公司, 兰州 730102;⁴深圳市老年医学研究所, 深圳 518020

摘要:为研究彩云木 *Synadenium grantii* 叶的化学成分及部分化合物体外抗炎活性, 本研究采用硅胶、Sephadex LH-20 等多种柱色谱进行分离纯化, 通过理化性质和 NMR 等波谱数据鉴定化合物的结构, 并对部分化合物进行抑制脂多糖诱导 RAW 264.7 细胞释放 NO 活性的测定。从彩云木叶二氯甲烷-甲醇(1:1)提取物中共分离得到了 10 个化合物, 分别鉴定为日尔曼醇(1)、大戟醇(2)、正二十八烷醇(3)、 β -谷甾醇(4)、豆甾醇(5)、ingol-7,8,12-triacetate-3-phenylacetate(6)、山奈酚-3-*O*- α -L-吡喃鼠李糖苷(7)、胡萝卜苷(8)、3,4,3'-三甲氧基鞣花酸-4'-*O*- β -D-吡喃葡萄糖苷(9)、山奈酚-3-*O*- β -D-吡喃葡萄糖苷(10)。其中 3 和 6~10 为首次从该种植物中分离得到, 3, 6, 8 和 9 为首次从聚菴大戟属植物中分离得到, 9 抑制 LPS 诱导 RAW 264.7 细胞释放 NO 的 IC₅₀ 值为 12.0 \pm 0.9 μ M, 显示较好的体外抗炎活性。

关键词:彩云木; 化学成分; ingol-7,8,12-triacetate 3-phenylacetate; 抗炎活性

中图分类号: R284.2

文献标识码: A

文章编号: 1001-6880(2020)10-1698-06

DOI: 10.16333/j.1001-6880.2020.10.010

Chemical constituents from the leaves of *Synadenium grantii* and their anti-inflammatory activity

YANG Hang¹, ZHOU Qing-ya², CHEN Yu¹, LU Yan-xia¹, LIU Meng-yuan¹, LI Lu-jun^{1,3,4*}, Paul W. Paré^{2*}¹National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Biotechnology of Chinese Traditional Medicine, Hubei University, Wuhan 430062, China;²Department of Chemistry & Biochemistry, Texas Tech University, Lubbock 79409, USA;³Gansu Herbal Medicine Planting Co., Ltd., Lanzhou 730102, China; ⁴Shenzhen Institute of Geriatrics, Shenzhen 518020, China

Abstract: To investigate the chemical constituents from the leaves of *Synadenium grantii* and their anti-inflammatory activities *in vitro*, various column chromatography techniques such as column chromatography on silica gel, Sephadex LH-20 were used to isolate and purify compounds and their structures were identified by spectral data including NMR and physicochemical properties. Some compounds were evaluated for their inhibitory effects on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells. Ten compounds were isolated and identified as germanicol (1), euphol (2), 1-octacosanol (3), β -sitosterol (4), stigmasterol (5), ingol 7,8,12-triacetate-3-phenylacetate (6), kaempferol-3-*O*- α -L-rhamnopyranoside (7), daucosterol (8), 3,3,4'-tri-*O*-methylellagic acid 4'-*O*- β -D-glucopyranoside (9), kaempferol-3-*O*- β -D-glucopyranoside (10). Compounds 3 and 6-10 were isolated from the species for the first time, among which compounds 3, 6, 8 and 9 were isolated from the plants in genus *Synadenium* for the first time. Compound 9 shows good anti-inflammatory activity *in vitro* with an IC₅₀ values of 12.0 \pm 0.9 μ M.

Key words: *Synadenium grantii*; chemical constituents; ingol 7,8,12-triacetate 3-phenylacetate; anti-inflammatory activity

收稿日期: 2020-04-27 接受日期: 2020-09-11

基金项目: 国家自然科学基金(81560703); 深圳市基础研究计划自由探索项目(JCYJ20170306171157738); 药物高通量筛选技术国家地方联合工程研究中心开放基金(M20181007); 药学“荆楚卓越人才”协同育人计划大学生创新训练计划(M20191002)

* 通信作者 E-mail: lilujunhuda@163.com, paul.pare@ttu.edu

彩云木 *Synadenium grantii* 为大戟科 (Euphorbiaceae) 聚苞大戟属 *Synadenium* 植物, 是一种原产于非洲东部多汁灌木, 后来作为一种观赏植物引入美洲和欧洲^[1], 又称“非洲乳木”。该木树枝折断或剥离茎皮, 会产生白色乳胶汁^[2]。临床报告指出接触该植物的乳胶汁, 脸和脖子产生象火烧一样的刺激感^[3]。巴西民间常把该植物乳胶汁作为一种传统药物用于多种疾病的治疗, 如过敏, 胃肠紊乱^[4], 肿瘤^[5]等。该植物的叶也具有广泛的药理活性, 研究表明彩云木叶乙醇提取物具有明显的镇痛、抗炎^[6], 抗菌^[7]、抗肿瘤、抗血管生成^[8]和改善痛经作用^[9]。Hassan 等^[10]发现其叶的氯仿提取物具有肿瘤细胞毒和抗寄生虫作用, 并从中得到两个新的二萜酯类成分。Andersen 等^[11]从中分离得到多个花色苷类成分。为了深入研究该植物化学资源, 继续寻找具有抗炎活性的化学成分, 本研究对其叶的二氯甲烷-甲醇(1:1)提取物的化学成分及其体外抗炎活性进行了研究, 以探明其抗炎生物活性物质基础。

1 材料与方法

1.1 仪器与材料

JEOL ECS 400 MHz 核磁共振仪 (Peabody, MA, USA); ESI-MS (API2000 三重四级杆质谱仪, Applied Biosystems, Foster City, CA); 分析和半制备型 HPLC 为 Agilent 1100 HPLC (DAD 检测器); 色谱柱为 Zorbax SB-C₁₈ (Agilent, 4.6 mm × 250 mm × 5 μm, 1 mL/min; 9.4 mm × 250 mm × 5 μm, 3 mL/min); 紫外分析仪 (Spectroline, Westbury, NY, USA); Buchi R-114 旋转蒸发仪; CO₂ 培养箱 (德国 Heraeus 公司); 超净工作台 (中国苏州安泰空气技术有限公司); XDS-1B 型倒置显微镜 (中国北京佳源兴业有限公司); 硅胶 60 (0.040 ~ 0.063 mm, EMD Millipore, Billerica, MA, USA); Sephadex LH-20 (GE healthcare Bio-sciences AB); MCI Gel CHP20P; 大孔树脂 HP-20 (日本, 三菱); 薄层硅胶板 GF 254 (Merck KGaA, Darmstadt Germany), 正己烷、乙酸乙酯、氯仿、甲醇 (Fisher Chemical, Certified ACS, Fair Lawn, NJ, USA); 其他试剂为分析纯; 二甲基亚砜 (DMSO)、噻唑蓝 (MTT)、脂多糖 (LPS) (Sigma 公司); DMEM 培养基购于 HyClone™ 公司; 胎牛血清 (FBS) 购于浙江天杭生物科技有限公司; NO 检测试剂盒 (上海碧云天生物科技有限公司)。

样品原料由埃及国家研究中心 Mohamed-Elamir

F. Hegazy 教授采集并鉴定为 *Synadenium grantii* Hook F. 的干燥叶, 标本 (编号 20161201) 存放于美国德州理工大学化学与生物化学系 Paul W. Paré 教授实验室。小鼠单核巨噬细胞 RAW264.7 由药物高通量筛选国家与地方联合工程研究中心提供。

1.2 提取与分离

干燥的彩云木叶 (900 g), 适当粉碎, 用 3 L CH₂Cl₂-MeOH (1:1, V/V) 混合液室温浸渍提取 3 次, 合并提取液减压浓缩除去溶剂, 得提取浸膏 63.5 g。取上述浸膏 46.9 g 经硅胶柱色谱 (0.040 ~ 0.063 mm) 分离, 以正己烷-乙酸乙酯系统梯度洗脱 (100:1 → 1:100), 得 62 个流分 F1 ~ F62。取流分 F15 经硅胶柱色谱, 正己烷-乙酸乙酯 (6:1) 洗脱后再经 Sephadex LH-20 柱用 CH₂Cl₂-MeOH (1:1) 洗脱得化合物 1 (20.0 mg), 流分 F19 经硅胶柱色谱由正己烷-乙酸乙酯 (20:1 → 4:1) 洗脱得化合物 2 (10.2 mg)。流分 F26 经硅胶柱色谱/正己烷-乙酸乙酯 (4:1) 得化合物 3 (3.6 mg), 流分 F30 经硅胶柱色谱用正己烷-乙酸乙酯 (4:1) 洗脱后得 3 个主要次级流分 F26a-F26c, F26a 经重结晶得化合物 4 (50.0 mg), F26c 再经硅胶柱色谱/正己烷-乙酸乙酯 (10:1) 得化合物 5 (40.1 mg); 流分 F38 上 Sephadex LH-20 柱经 CH₂Cl₂-MeOH (1:1) 洗脱得 2 个主要次级流分 F38a 和 F38b, F38a 经 RP-HPLC/乙腈-水 (4:1 → 9:1) 梯度洗脱得化合物 6 (15.3 mg)。流分 F60 经硅胶柱由 CH₂Cl₂-MeOH-H₂O (200:10:1) 洗脱得 3 个次级流分 F60a ~ F60c, F60a 经再硅胶柱分离得化合物 8 (30.6 mg), F60c 经 Sephadex LH-20 柱 MeOH 洗脱得化合物 7 (8 mg)。流分 F62 用大孔吸附树脂依次用纯水、50% 和 95% 乙醇水溶液洗脱, 取 50% 乙醇洗脱液经硅胶柱由 CH₂Cl₂-MeOH (20:1 → 5:1) 梯度洗脱得 4 个次级流分 F62a ~ F62d, F62a 经 RP-HPLC 用 MeOH-H₂O 梯度洗脱得化合物 9 (9.4 mg), F62d 经 Sephadex LH-20 柱以 MeOH 洗脱得化合物 10 (7.0 mg)。

1.3 体外细胞毒和抗炎活性筛选实验

1.3.1 细胞毒实验

取对数生长期 RAW264.7 小鼠巨噬细胞按 1 × 10⁵ 个/mL, 200 μL/孔接种于 96 孔板中, 用含 10% FBS 的 DMEM 培养基于 37 °C、5% CO₂ 培养箱中培养 24 h 后弃培养基, 分别加入不同浓度的部分单体化合物至 0、3.125、6.25、12.5、25、50 μM 继续培养 24 h, 每组设 3 个复孔, MTT 法测定细胞存活率。

1.3.2 抗炎活性筛选

取单体化合物分别用 DMSO 配制成 50 μM 的溶液作为储备液,加药时用无血清培养基稀释。同样条件培养细胞 24 h 后弃培养基,加入 100 μL 浓度为 0、3.125、6.25、12.5、25、50 μM 的系列单体化合物溶液孵育 4 h,每组设 3 个复孔,加入终质量浓度为 1 $\mu\text{g}/\text{mL}$ 的 LPS 刺激细胞继续培养 20 h。离心,取上清液,移至新的 96 孔板,按照试剂盒说明书规定的方法,在 540 nm 波长下用酶标仪测定 NO,计算最大半数抑制浓度 (IC_{50}) 值。

2 实验结果

2.1 结构鉴定

化合物 1 白色针晶(正己烷-乙酸乙酯); mp. 179 ~ 181 $^{\circ}\text{C}$, ESI-MS: m/z 465 $[\text{M} + \text{K}]^+$ 。 ^1H NMR(400 MHz, CDCl_3) δ : 0.75 (3H, s, H-23), 0.83 (3H, s, H-25), 0.89 (3H, s, H-24), 0.93 (6H, s, H-26, 27), 0.94 (3H, s, H-28), 1.03 (3H, s, H-29), 1.08 (3H, s, H-30), 3.46 (1H, dd, $J = 5.6, 11.0$ Hz, H-3), 4.86 (1H, s, H-19); ^{13}C NMR (100 MHz, CDCl_3) δ : 142.9 (C-18), 129.8 (C-19), 76.4 (C-3), 51.1 (C-5), 49.3 (C-9), 43.5 (C-14), 41.1 (C-8), 38.9 (C-4, 13), 38.5 (C-1), 37.8 (C-16), 37.7 (C-22), 37.5 (C-10), 34.6 (C-7), 34.5 (C-17), 33.5 (C-21), 32.3 (C-20), 31.5 (C-29), 29.3 (C-30), 28.4 (C-23), 27.6 (C-15), 26.4 (C-12), 25.6 (C-2), 25.4 (C-28), 22.3 (C-26), 21.1 (C-11), 18.4 (C-6), 16.7 (C-25), 16.2 (C-24), 14.8 (C-27)。以上数据与文献^[12]基本一致,故化合物 1 鉴定为日尔曼醇。

化合物 2 白色针晶(正己烷-乙酸乙酯); mp. 116 ~ 118 $^{\circ}\text{C}$, ESI-MS: m/z 465 $[\text{M} + \text{K}]^+$ 。 ^1H NMR(400 MHz, CDCl_3) δ : 0.76 (3H, s, H-18), 0.79 (3H, s, H-29), 0.86 (3H, s, H-30), 0.89 (3H, d, $J = 6.4$ Hz, H-21), 0.96 (3H, s, H-28), 1.00 (3H, s, H-19), 1.60 (3H, s, H-26), 1.68 (3H, s, H-27), 3.24 (1H, dd, $J = 11.8, 4.6$ Hz, H-3), 5.10 (1H, t, $J = 7.0$ Hz, H-24); ^{13}C NMR(100 MHz, CDCl_3) δ : 134.2 (C-9), 133.7 (C-8), 131.1 (C-25), 125.4 (C-24), 79.2 (C-3), 51.1 (C-17), 50.2 (C-5), 50.1 (C-14), 44.2 (C-13), 39.1 (C-4), 37.4 (C-20), 36.6 (C-10), 36.5 (C-1), 35.4 (C-22), 31.2 (C-16), 30.9 (C-15), 28.2 (C-12), 28.1 (C-29), 27.8 (C-7), 26.6 (C-28), 25.9 (C-27), 25.1 (C-23), 24.5 (C-2), 21.6 (C-11), 20.3 (C-19), 19.1 (C-21), 18.8 (C-6), 17.8 (C-

26), 15.7 (C-18), 15.6 (C-30)。以上数据与文献^[13]基本一致,故化合物 2 鉴定为大戟醇。

化合物 3 白色粉末; ESI-MS: m/z 392 $[\text{M} - \text{H}_2\text{O}]^+$ 。 ^1H NMR(400 MHz, CDCl_3) δ : 0.88 (3H, t, $J = 6.5$ Hz, H-28), 1.26 (- CH_2), 3.65 (2H, q, $J = 6.6$ Hz, H-1); ^{13}C NMR (100 MHz, CDCl_3) δ : 63.3 (C-1), 33.0, 32.1, 29.9, 29.8, 29.6, 29.5, 25.9, 22.9 (多个亚甲基 C 信号), 14.3 (C-28)。以上数据与文献^[14]基本一致,故化合物 3 鉴定为正二十八烷醇。

化合物 4 无色针晶(正己烷-乙酸乙酯); mp. 136 ~ 138 $^{\circ}\text{C}$ 。 ^1H NMR(400 MHz, CDCl_3) δ : 5.35 (1H, d, $J = 5.2$ Hz, H-6), 3.52 (1H, m, H-3 α), 1.00 (3H, s, H-19), 0.92 (3H, d, $J = 6.5$ Hz, H-21), 0.84 (3H, t, $J = 7.6$ Hz, H-29), 0.83 (3H, d, $J = 7.0$ Hz, H-26), 0.81 (3H, d, $J = 6.9$ Hz, H-27), 0.68 (3H, s, H-18); ^{13}C NMR (100 MHz, CDCl_3) δ : 140.9 (C-5), 121.8 (C-6), 71.9 (C-3), 56.9 (C-14), 56.2 (C-17), 50.2 (C-9), 45.9 (C-24), 42.4 (C-4), 42.4 (C-13), 39.9 (C-12), 37.4 (C-1), 36.6 (C-10), 36.2 (C-20), 34.0 (C-22), 32.0 (C-7), 32.0 (C-8), 31.7 (C-2), 29.3 (C-25), 28.3 (C-16), 26.2 (C-23), 24.4 (C-15), 23.2 (C-28), 21.2 (C-11), 19.9 (C-27), 19.5 (C-19), 19.1 (C-21), 18.9 (C-26), 12.1 (C-29), 11.9 (C-18)。以上数据与文献^[15]基本一致,故化合物 4 鉴定为 β -谷甾醇。

化合物 5 白色针晶(乙酸乙酯); mp. 165 ~ 167 $^{\circ}\text{C}$ 。 ^1H NMR (400 MHz, CDCl_3) δ : 5.36 (1H, br. d, $J = 5.0$ Hz, H-6), 3.55 (1H, m, H-3), 0.69 (3H, s, CH_3 -18), 0.83 (3H, s, CH_3 -19), 0.91 (3H, d, $J = 6.0$ Hz, H-21), 5.13 (1H, dd, $J = 8.0, 15.1$ Hz, H-22), 5.01 (1H, dd, $J = 8.0, 15.1$ Hz, H-23), 0.84 (3H, d, $J = 6.3$ Hz, CH_3 -26), 0.79 (3H, d, $J = 5.5$ Hz, CH_3 -27), 0.81 (3H, t, $J = 7.4$ Hz, CH_3 -29); ^{13}C NMR (100 MHz, CDCl_3) δ : 141.0 (C-5), 138.5 (C-22), 129.6 (C-23), 121.9 (C-6), 72.1 (C-3), 57.1 (C-14), 50.4 (C-9), 57.0 (C-17), 51.5 (C-24), 42.6 (C-13), 42.5 (C-20), 40.6 (C-4), 40.0 (C-12), 37.5 (C-1), 36.8 (C-10), 32.2 (C-7), 32.2 (C-8), 32.0 (C-2), 31.9 (C-25), 29.1 (C-16), 25.6 (C-28), 24.6 (C-15), 21.4 (C-27), 21.2 (C-11), 20.2 (C-21), 19.6 (C-19), 19.2 (C-26), 12.5 (C-29), 12.3 (C-18)。以上数据与文献^[16]报道一致,故鉴定

化合物 5 为豆甾醇。

化合物 6 白色粉末;ESI-MS: m/z 611 [M + H]⁺。¹H NMR (400 MHz, CDCl₃) δ : 2.76 (1H, dd, $J = 15.0, 9.0$ Hz, H-1'), 1.67 (1H, d, $J = 15.0$ Hz, H-1'), 2.50 (1H, m, H-2), 5.14 (1H, d, $J = 8.6$ Hz, H-3), 5.39 (1H, br s, H-5), 5.14 (1H, br s, H-7), 4.52 (1H, dd, $J = 1.9, 10.7$ Hz, H-8), 1.09 (1H, dd, $J = 9.0, 10.9$ Hz, H-9), 1.02 (1H, dd, $J = 9.0, 10.9$ Hz, H-11), 4.81 (1H, dd, $J = 3.4, 10.9$ Hz, H-12), 2.86 (1H, qd, $J = 3.8, 7.1$ Hz, H-13), 0.91 (3H, d, $J = 7.5$ Hz, H-16), 2.06 (3H, d, $J = 1.2$ Hz, H-7), 1.04 (3H, s, H-18), 0.81 (3H, s, H-19), 1.04 (3H, d, $J = 7.1$ Hz, H-20), 1.96, 2.06, 2.09 (各 3H, s, 3 \times CH₃COO), 3.70 (2H, br s, H-7'), 7.26 ~ 7.33 (5H, m, H-2', 6', 3', 5', 4');¹³C NMR (100 MHz, CDCl₃) δ : 207.7 (C-14), 170.5, 170.8, 170.4 (3 \times CH₃CO), 170.3 (C-8'), 139.4 (C-6), 133.8 (C-1'), 129.3 (C-3', 5'), 128.6 (C-2', 6'), 127.2 (C-4'), 117.3 (C-5), 77.0 (C-7), 76.9 (C-3), 73.4 (C-4), 71.6 (C-8), 71.2 (C-15), 71.1 (C-16), 70.7 (C-12), 43.1 (C-13), 41.5 (C-7'), 31.5 (C-1), 29.8 (C-2), 29.6 (C-11), 29.2 (C-18), 24.7 (C-9), 20.7, 21.0, 21.1 (3 \times CH₃CO), 19.4 (C-10), 17.6 (C-17), 16.2 (C-19), 13.5 (C-20)。以上数据与文献^[17]基本一致,故化合物 6 鉴定为 Ingol 7,8,12-triacetate 3-phenylacetate。

化合物 7 黄色粉末;ESI-MS m/z : 455 [M + Na]⁺,¹H NMR (400 MHz, (CD₃)₂CO) δ : 0.90 (3H, d, $J = 5.8$ Hz, H-6''), 3.86 (1H, m, H-2''), 3.69 (1H, m, H-3''), 3.30 (2H, m, H-4'', 5''), 5.54 (1H, d, $J = 1.2$ Hz, H-1''), 6.27 (1H, br s, H-6), 6.47 (1H, br s, H-8), 6.91 (2H, d, $J = 8.4$ Hz, H-3', 5'), 7.80 (2H, d, $J = 8.4$ Hz, H-2', 6'), 12.72 (1H, s, 5-OH), 4.20, 3.86 (各 1H, br s, 7, 4'-OH);¹³C NMR (100 MHz, (CD₃)₂CO) δ : 179.3 (C-4), 164.9 (C-7), 163.2 (C-5), 161.0 (C-4'), 158.4 (C-2), 158.0 (C-9), 135.7 (C-3), 131.7 (C-2', 6'), 122.5 (C-1'), 116.3 (C-3', 5'), 105.8 (C-10), 102.6 (C-1''), 99.5 (C-6), 94.5 (C-8), 72.9 (C-4''), 72.1 (C-2''), 71.5 (C-3''), 71.3 (C-5''), 17.8 (C-6'')。以上数据与文献^[18]基本一致,故化合物 7 鉴定为山柰酚-3-*O*- α -*L*-吡喃鼠李糖苷。

化合物 8 白色粉末 (氯仿-甲醇);¹H NMR

(400 MHz, DMSO-*d*₆) δ : 5.33 (1H, s, H-6), 4.42 (1H, t, $J = 5.8$ Hz, H-3), 4.22 (1H, d, $J = 7.8$ Hz, H-1'), 0.65 (3H, s, CH₃-18), 0.95 (3H, s, CH₃-19), 0.90 (3H, d, $J = 6.5$ Hz, CH₃-21), 0.83 (3H, t, $J = 6.2$ Hz, H-29), 0.81 (3H, d, $J = 7.0$ Hz, H-26), 0.79 (3H, d, $J = 6.9$ Hz, H-27);¹³C NMR (100 MHz, DMSO-*d*₆) δ : 141.3 (C-5), 122.3 (C-6), 100.8 (C-1'), 79.0 (C-3), 56.2 (C-14), 55.4 (C-17), 49.6 (C-9), 45.1 (C-24), 41.9 (C-13), 39.3 (C-4), 38.2 (C-12), 36.8 (C-1), 36.2 (C-10), 35.5 (C-20), 33.4 (C-22), 31.5 (C-8), 31.4 (C-7), 29.3 (C-2), 28.7 (C-25), 27.8 (C-16), 25.4 (C-23), 23.9 (C-15), 22.6 (C-28), 20.6 (C-11), 19.8 (C-27), 19.1 (C-26), 18.9 (C-19), 18.6 (C-21), 11.8 (C-29), 11.7 (C-18), 73.5 (C-2'), 76.9 (C-3'), 70.1 (C-4'), 76.8 (C-5'), 61.1 (C-6')。以上数据与文献^[19]基本一致,故化合物 8 鉴定为胡萝卜苷。

化合物 9 白色粉末 (甲醇); mp. 266 ~ 267 °C。¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.85 (1H, s, H-5'), 7.66 (1H, s, H-5), 5.48 (1H, d, $J = 8.4$ Hz, H-1''), 5.17 (1H, d, $J = 8.4$ Hz, 2''-OH), 5.08 (1H, d, $J = 5.3$ Hz, 4''-OH), 4.58 (1H, t, $J = 5.3$ Hz, 3''-OH), 4.10 (3H, s, 3-OCH₃), 4.05 (3H, s, 3'-OCH₃), 4.01 (3H, s, 4-OCH₃), 3.70 (1H, m, H-2''), 3.52 (1H, m, H-3''), 3.36 (2H, m, H-4'', 5''), 3.24 (2H, m, H-6'');¹³C NMR (100 MHz, DMSO-*d*₆) δ : 158.5 (C-7'), 158.2 (C-7), 154.4 (C-4'), 151.9 (C-4), 141.9 (C-2'), 141.3 (C-3'), 141.2 (C-2), 140.9 (C-3), 113.7 (C-6'), 112.9 (C-1'), 112.7 (C-6), 112.4 (C-1), 112.1 (C-5), 107.6 (C-5'), 101.3 (C-1''), 77.3 (C-3''), 76.5 (C-5''), 73.3 (C-2''), 69.5 (C-4''), 61.7 (3'-OCH₃), 61.4 (3-OCH₃), 60.5 (C-6''), 56.8 (4-OCH₃)。以上数据与文献^[20]基本一致,故化合物 9 鉴定为 3,4,3'-三甲氧基鞣花酸-4'-*O*- β -*D*-吡喃葡萄糖苷。

化合物 10 黄色粉末;¹H NMR (400 MHz, CD₃OD) δ : 8.06 (2H, d, $J = 8.9$ Hz, H-2', 6'), 6.89 (2H, d, $J = 8.9$ Hz, H-1', 5'), 6.41 (1H, d, $J = 2.1$ Hz, H-8), 6.21 (1H, d, $J = 2.1$ Hz, H-6), 5.26 (2H, d, $J = 7.5$ Hz, H-1''), 3.69 (1H, dd, $J = 2.3, 11.9$ Hz, H _{α} -6''), 3.53 (1H, dd, $J = 5.4, 11.9$ Hz, H _{β} -6''), 3.43 (2H, m, H-2'', 5''), 3.19 (2H, m, H-3'', 4'');¹³C NMR (100 MHz, CD₃OD) δ : 179.5 (C-4),

166.2(C-7), 163.1(C-5), 161.6(C-4'), 159.1(C-2), 158.6(C-9), 135.4(C-3), 132.3(C-2', 6'), 122.8(C-1'), 116.1(C-3', 5'), 105.7(C-10), 104.0(C-1''), 99.9(C-6), 94.8(C-8), 78.5(C-5''), 78.1(C-3''), 75.7(C-2''), 71.4(C-4''), 62.6(C-6'')。以上数据与文献^[21]基本一致,故化合物**10**鉴定为山奈酚-3-O-β-D-吡喃葡萄糖苷。

2.2 部分化合物细胞毒和抗炎活性

部分化合物细胞毒性和抗炎活性结果如表1所示,化合物**1**、**2**、**6**、**7**、**9**和**10**在50 μM浓度下对细胞没有明显毒性。化合物**9**抑制LPS诱导RAW 264.7细胞释放NO的IC₅₀值为12.0 ± 0.9 μM,显示出了较强的抑制活性。化合物**1**、**2**、**7**和**10**的IC₅₀值分别为28.0 ± 1.6、30.8 ± 2.0、38.4 ± 2.1和33.5 ± 1.7 μM,化合物**6**的IC₅₀值大于50 μM。

表1 部分化合物的细胞毒性和抗炎活性

Table 1 Cytotoxicity and anti-inflammatory activity of some compounds

化合物 Compound	细胞毒性 Cytotoxic activity	抗炎活性 Anti-inflammatory activity
	Toxic dose(μM)	IC ₅₀ (μM)
1	>50	28.0 ± 1.6
2	>50	30.8 ± 2.0
6	>50	>50
7	>50	38.4 ± 2.1
9	>50	12.0 ± 0.9
10	>50	33.5 ± 1.7

3 结论与讨论

本研究对彩云木的二氯甲烷-甲醇(1:1)提取物的化学成分及其体外抗炎活性进行了研究,从中分离鉴定了10个化合物,化合物类型主要包括三萜(2个)、甾醇型二萜(1个)、黄酮苷类(2个)、甾醇及其苷类(3个)、多酚类(1个)和脂肪醇(1个)。其中化合物**3**、**6**~**10**为首次从该种植物中分离得到,化合物**3**、**6**、**8**和**9**为首次从聚苞大戟属植物中分离得到。

以脂多糖(LPS)诱导RAW264.7细胞为体外炎症模型,通过抑制一氧化氮(NO)生成实验评价部分化合物抗炎活性,其中**1**、**2**、**7**和**10**具有较弱的抗炎活性,多酚类化合物**9**显示出较好的抗炎活性,有潜力成为治疗炎症性相关疾病的新型药物资源。该研究丰富了彩云木叶的化学成分,解析其抗炎活性物

质基础,为其药物研发及利用提供了科学依据。

致谢:感谢埃及国家研究中心植物化学系 Mohamed-Elamir F. Hegazy 教授提供的植物原料及药材提取工作。

参考文献

- Jesuino FWDR, Reis JP, Whitaker JCP, et al. Effect of *Synadenium grantii* and its isolated compound on dysmenorrhea behavior model in mice [J]. *Inflammopharmacology*, 2019, 27:613-620.
- Duarte MDR, Jurgensen I, Awaad AS, et al. African milkbush (*Synadenium grantii* Hook. f.): ethnopharmacological, chemical and morpho-anatomical aspects [J]. *Recent Progress in Medicinal Plants*, 2010, 27:109-117.
- Kinghorn AD, Major skin-irritant principle from *Synadenium grantii* [J]. *J Pharm Sci*, 1980, 69:1446-1447.
- Costa LLG, David VC, Pinto RMC, et al. Anti-ulcer activity of *Synadenium grantii* latex [J]. *Rev Bras Farmacog*, 2012, 22:1070-1078.
- De Oliveira TL, Munhoz AC, Lemes BM, et al. Antitumoural effect of *Synadenium grantii* Hook f. (Euphorbiaceae) latex [J]. *J Ethnopharmacol*, 2013, 150:263-269.
- Borges R, Nascimento MV, de Carvalho AA, et al. Antinociceptive and anti-inflammatory activities of the ethanolic extract from *Synadenium umbellatum* Pax. (Euphorbiaceae) leaves and its fractions [J]. *Evid Based Complement Alternat Med*, 2013:715650.
- Adhav M, Patel B, Gharia A. Evaluation of antimicrobial agent from leaves of *Synadenium grantii* Hk. f. *Bot. Mag [J]*. *Biosci Biotechnol Res Asia*, 2010, 7:919-924.
- Nogueira IAL, Leao ABB, Vieira MS, et al. Antitumoural and antiangiogenic activity of *Synadenium umbellatum* Pax [J]. *J Ethnopharmacol*, 2008, 120:474-478.
- Jesuino FWDR, Reis JP, Whitaker JCP, et al. Effect of *Synadenium grantii* and its isolated compound on dysmenorrhea behavior model in mice [J]. *Inflammopharmacology*, 2019, 27:613-620.
- Hassan EM, Mohammed MMD, Mohamed SM. Two new phorbol-type diterpene esters from *Synadenium grantii* Hook f. leaves [J]. *Rec Nat Prod*, 2012, 6:255-262.
- Andersen φM, Jordheim M, Byamukama R, et al. Anthocyanins with unusual furanose sugar (apiose) from leaves of *Synadenium grantii* (Euphorbiaceae) [J]. *Phytochemistry*, 2010, 71:1558-1563.
- Wang ZZ, Li J, Tang XL, et al. Triterpenes and steroids from semi-mangrove plant *Hibiscus tiliaceus* [J]. *Chin J Nat Med (中国天然药物)*, 2011, 9:190-192.

- 13 Cao D, Su YL, Yang JS. Triterpene constituents from *Euphorbia nemtoocypha* Hand-Mazz [J]. Acta Pharm Sin (药学学报), 1992, 27: 445-451.
- 14 Zhao J, Yang WJ, Ren Y, et al. Chemical constituents of *Caparis spinosa* L. [J]. Nat Prod Res Dev (天然产物研究与开发), 2012, 24: 52-54.
- 15 Li XJ, Kim KW, Oh HC, et al. Chemical constituents from stems of *Acanthopanax henryi* [J]. Chin Tradit Herb Drugs (中草药), 2019, 50: 1055-1060.
- 16 Zhao Q, Liang RJ, Zhang YJ, et al. Chemical constituents in roots of *Phyllanthus emblica* [J]. Chin Tradit Herb Drugs (中草药), 2013, 44: 133-136.
- 17 Daoubi M, Marquez N, Mazoir N, et al. Isolation of new phenylacetylating derivatives that reactivate HIV-1 latency and a novel spirotriterpenoid from *Euphorbia officinarum* latex [J]. Bioorg Med Chem, 2007, 15: 4577-4584.
- 18 Fang JJ, Ye G. Flavonoids and xanthenes from *Tripterospermum chinense* [J]. Chem Nat Compd, 2008, 44: 514-515.
- 19 Ye JH, Lv J, Yu W, et al. Studies on chemical constituents from *Isodon eriocalyx* distributed in Hezhang [J]. Chin Tradit Herb Drugs (中草药), 2019, 50: 2296-2301.
- 20 Xiao CM, Li YY, Hu R, et al. Studies on the chemical constituents of phenolic acids from *Potentilla discolor* [J]. West China J Pharm Sci (华西药学杂志), 2013, 28: 10-12.
- 21 Feng WS, Hao ZY, Zheng XK, et al. Chemical constituents from leaves of *Celastrus gemmatus* Loes [J]. Acta Pharm Sin (药学学报), 2007, 42: 625-630.

(上接第 1643 页)

- 16 Xie X, Peng J, Chang X, et al. Activation of RhoA/ROCK regulates NF- κ B signaling pathway in experimental diabetic nephropathy. [J]. Mol Cell Endocrinol, 2013, 369(1-2): 86-97.
- 17 Gao SY, Li CY, Chen J, et al. Rho-ROCK signal pathway regulates microtubule-based process formation of cultured podocytes--inhibition of ROCK promoted process elongation [J]. Nephron Exp Nephrol, 2004, 97(2): e49-e61.
- 18 Wang L, Ellis MJ, Gomez JA, et al. Mechanisms of the proteinuria induced by Rho GTPases [J]. Kidney Int, 2012, 81: 1075-1085.
- 19 Gu L, Gao Q, Ni L, et al. Fasudil inhibits epithelial-myofibroblast transdifferentiation of human renal tubular epithelial HK-2 cells induced by high glucose. [J]. Chem Pharm Bull (Tokyo), 2013, 61: 688-694.
- 20 Komers R. Rho kinase inhibition in diabetic kidney disease. [J]. Br J Clin Pharmacol, 2013, 76: 551-559.